S3-guideline "helicobacter pylori and gastroduodenal ulcer disease" of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for hygiene and microbiology, society for pediatric gastroenterology and nutrition e.V., German Society for rheumatology, AWMF-registration-no. 021/001

Zeitschrift fur Gastroenterologie

Volumn 47, Issue 12, 2009, Pages 1230-1263

  Fischbach, Wolfgang ^a   Malfertheiner, P ^b   Hoffmann, J C ^c   Bolten, W ^d   Bornschein, J ^b   Gotze O ^e   Hohne W ^f   Kist, M ^g   Koletzko, S ^h   Labenz, J ⁱ   Layer, P ^j   Miehlke, St ^k   Morgner, A ^k   Peitz, U ^l   Preiss J ^f   Prinz, C ^m   Roslen, U ^j   Schmidt, W ^e   Schwarzer, A ^h   Suerbaum, St ⁿ   Timmer, A ^o   Treiber, G ^p   Vleth, M ^q   more..

^a KLINIKUM ASCHAFFENBURG   (Germany)

^b Klinik für Gastroenterologie Hepatologie und Infektiotogie   (Germany)

^c St Marienkrankenhaus   (Germany)

^d Klaus Miehlke Klinik   (Germany)

^e ST JOSEF HOSPITAL   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF FREIBURG   (Germany)

^h LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

ⁱ Ev Jung Stilling Krankenhaus   (Germany)

^j ISRAELITISCHES KRANKENHAUS   (Germany)

^k UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^l Raphaels Klinik Munster GmbH   (Germany)

^m TECHNICAL UNIVERSITY OF MUNICH   (Germany)

ⁿ LEIBNIZ UNIVERSITY HANNOVER   (Germany)

^o Deutsches Cochrane Zentrum   (Germany)

^p SAARLAND UNIVERSITY   (Germany)

^q INSTITUTE OF PATHOLOGY   (Germany)

more..

Author keywords

Gastroduodenal ulcer; Helicobacter pylori; Ulcer disease

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; BIOLOGICAL MARKER; BISMUTH SALT; CELECOXIB; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; CLOPIDOGREL; CYCLOPHOSPHAMIDE; DICLOFENAC; ESOMEPRAZOLE; IMIDAZOLE; IMMUNOGLOBULIN G ANTIBODY; LANSOPRAZOLE; LEVOFLOXACIN; METRONIDAZOLE; MOXIFLOXACIN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; OXALIPLATIN; PANTOPRAZOLE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RABEPRAZOLE; RIFABUTIN; RITUXIMAB; TETRACYCLINE;

ADOLESCENT DISEASE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; BACTERIAL TRANSMISSION; BACTERIUM CULTURE; BACTERIUM DETECTION; BONE MARROW BIOPSY; CANCER CLASSIFICATION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CHILDHOOD DISEASE; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONSENSUS DEVELOPMENT; DISEASE ASSOCIATION; DRUG DOSE SEQUENCE; DRUG EFFICACY; DRUG TOLERABILITY; ECHOGRAPHY; ENDOSCOPIC ECHOGRAPHY; EPSILOMETER TEST; ERADICATION THERAPY; EVIDENCE BASED PRACTICE; GASTRODUODENAL ULCER; GASTROINTESTINAL BIOPSY; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GERMANY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; IRON DEFICIENCY ANEMIA; LOW DRUG DOSE; MARGINAL ZONE LYMPHOMA; MEDICAL SOCIETY; NONHUMAN; PATIENT MONITORING; PATIENT REFERRAL; POLYMERASE CHAIN REACTION; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SERODIAGNOSIS; STOMACH CARCINOMA; STOMACH LYMPHOMA; TREATMENT CONTRAINDICATION; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT INDICATION;

GASTROENTERITIS; GASTROENTEROLOGY; GERMANY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER;

EID: 75749096790     PISSN: 00442771     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109855     Document Type: Review

References (489)

1. Graham DY, Adam E Reddy GT et al. Seroepidemiology of Helicobacter pylori infection in India. Comparison of developing and developed countries. Dig Dis Sci 1991; 36 (8): 1084-1088
2. Megraud F, Brassens-Rabbe MP, Denis F et al. Seroepidemiology of Campylobacter pylori infection in various populations. J Clin Microbiol 1989; 27 (8): 1870-1873
3. Redlinger T, O'Rourke K, Goodman KJ. Age distribution of Helicobacter pylori seroprevalence among young children in a United States/Mexico border community: evidence for transitory infection. Am J Epidemiol 1999; 150 (3): 225-230
4. Taylor DN, Blaser MJ. The epidemiology of Helicobacter pylori infection. Epidemiol Rev 1991; 13: 42-59
5. Malaty HM, Graham DY. Importance of childhood socioeconomic status on the current prevalence of Helicobacter pylori infection. Gut 1994; 35 (6): 742-745
6. Graham DY, Malaty HM, Evans DG et al. Epidemiology of Helicobacter pylori in an asymptomatic population in the United States. Effect of age, race, and socioeconomic status. Gastroenterology 1991; 100 (6): 1495-1501
7. Malaty HM, Evans DG, Evans Jr DJ et al. Helicobacter pylori in Hispanics: comparison with blacks and whites of similar age and socioeconomic class. Gastroenterology 1992; 103 (3): 813-816
8. Malaty HM, Engstrand L Pedersen NL et al. Helicobacter pylori infection: genetic and environmental influences. A study of twins. Ann Intern Med 1994; 120(12): 982-986
9. Perez-Perez Gl, Olivares AZ, Foo FY et al. Seroprevalence of Helicobacter pylori in New York City populations originating in East Asia, J Urban Health 2005; 82 (3): 510-516
10. Malaty HM, Kim JG, Kim SD et al. Prevalence of Helicobacter pylori infection in Korean children: inverse relation to socioeconomic status despite a uniformly high prevalence in adults. Am J Epidemiol 1996; 143 (3): 257-262
11. Banatvala N, Mayo K, Megraud F et al. The cohort effect and Helicobacter pylori. J Infect Dis 1993; 168 (1): 219-221
12. Roosendaal R, Kuipers EJ, Buitenwerf J et al. Helicobacter pylori and the birth cohort effect: evidence of a continuous decrease of infection rates in childhood. Am J Gastroenterol 1997; 92 (9): 1480-1482
13. al-Moagel MA, Evans DG, Abdulghani ME et al. Prevalence of Helicobacter (formerly Campylobacter) pylori infection in Saudia Arabia, and comparison of those with and without upper gastrointestinal symptoms. Am J Gastroenterol 1990; 85 (8): 944-948
14. Grimm W, Fischbach W. [Helicobacter pylori infection in children and juveniles: an epidemiological study on prevalence, socio-economic factors and symptoms]. Dtsch Med Wochenschr 2003; 128 (37): 1878-1883
15. Rothenbacher D, Bode G, Berg G et al. Prevalence and determinants of Helicobacter pylori infection in preschool children: a population-based study from Germany. Int J Epidemiol 1998; 27 (1 ): 135-141
16. Brenner H, Weyermann M, Rothenbacher D. Clustering of Helicobacter pylori infection in couples: differences between high- and low-prevalence population groups. Ann Epidemiol 2006; 16 (7): 516-520
17. Kumagai T, Malaty HM, Graham DY et al. Acquisition versus loss of Helicobacter pylori infection in japan: results from an 8-year birth cohort study, J Infect Dis 1998; 178(3): 717-721
18. Tkachenko MA, Zhannat NZ, Erman LV et al. Dramatic Changes in the Prevalence of Helicobacter pylori Infection During Childhood: A 10-year Follow-up Study in Russia. J Pediatr Gastroenterol Nutr 2007; 45 (4): 428-432
19. Parsonnet J. The incidence of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9 (Suppl 2): 45-51
20. ParsonnetJ, Shmuely H, Haggerty T. Fecal and oral shedding of Helicobacter pylori from healthy infected adults. Jama 1999; 282 (23): 2240-2245
21. Leung WK, Siu KL Kwok CK et al. Isolation of Helicobacter pylori from vomitus in children and its implication in gastro-oral transmission. Am J Gastroenterol 1999; 94(10): 2881-2884
22. Laporte R, Pernes P, Pronnier P et al. Acquisition of Helicobacter pylori infection after outbreaks of gastroenteritis: prospective cohort survey in institutionalised young people. Bmj 2004; 329 (7459): 204-205
23. Handt LK, Fox JG, Dewhirst FE et al. Helicobacter pylori isolated from the domestic cat: public health implications. Infect Immun 1994; 62 (6): 2367-2374
24. Dore MP, Sepulveda AR, Osato MS et al. Helicobacter pylori in sheep milk. Lancet 1999; 354 (9173): 132
25. Dore MP, Sepulveda AR, El-Zimaity H et al. Isolation of Helicobacter pylori from sheep-implications for transmission to humans. Am J Gastroenterol 2001 ; 96 (5): 1396-1401
26. Rocha GA, Rocha AM, Silva LD et al. Transmission of Helicobacter pylori infection in families of preschool-aged children from Minas Gerais, Brazil. Trop Med Int Health 2003; 8(11): 987-991
27. Rothenbacher D, Winkler M, Gonser T et al. Role of infected parents in transmission of helicobacter pylori to their children. Pediatr Infect Dis J 2002; 21 (7): 674-679
28. Kivi M.Johansson AL, Reilly M et al. Helicobacter pylori status in family members as risk factors for infection in children. Epidemiol Infect 2005; 133 (4): 645-652
29. Tindberg Y, Bengtsson C Granath F et al. Helicobacter pylori infection in Swedish school children: lack of evidence of child-to-child transmission outside the family. Gastroenterology 2001 ; 121 (2): 310-316
30. Han SR, Zschausch HC, Meyer HG et al. Helicobacter pylori: clonal population structure and restricted transmission within families revealed by molecular typing. J Clin Microbiol 2000; 38 (10): 3646-3651
31. Kivi M, Tmdberg Y, Sorberg M et al. Concordance of Helicobacter pylori strains within families.J Clin Microbiol 2003; 41 (12): 5604-5608
32. Mendall MA, Goggin PM, Molineaux N et al. Childhood living conditions and Helicobacter pylori seropositivity in adult life. Lancet 1992; 339 (8798): 896-897
33. Goodman KJ, Correa P. Transmission of Helicobacter pylori among siblings. Lancet 2000; 355 (9201): 358-362
34. Rowland M, Daly L, Vaughan M et al. Age-specific incidence of Helicobacter pylori. Gastroenterology 2006; 130 (1): 65-72, quiz 211
35. Goodman KJ, Correa P, Tengana Aux HJ et al. Helicobacter pylori infection in the Colombian Andes: a population-based study of transmission pathways. Am J Epidemiol 1996; 144 (3): 290-299
36. Glynn MK, Friedman CR, Gold BD et al. Seroincidence of Helicobacter pylori infection in a cohort of rural Bolivian children: acquisition and analysis of possible risk factors. Clin Infect Dis 2002; 35 (9): 1059-1065
37. Aguemon BD, Struelens MJ, Massougbodji A et al. Prevalence and riskfactors for Helicobacter pylori infection in urban and rural Beninese populations. Clin Microbiol Infect 2005; 11 (8): 611-617
38. Klein PD, Graham DY, GaillourA et al. Water source as risk factor for Helicobacter pylori infection in Peruvian children. Gastrointestinal Physiology Working Group. Lancet 1991; 337 (8756): 1503-1506
39. Hulten K, Han SW, Enroth H et al. Helicobacter pylori in the drinking water in Peru. Gastroenterology 1996; 110(4): 1031-1035
40. Lu Y, Redlinger TE, Avitia R et al. Isolation and genotyping of Helicobacter pylori from untreated municipal wastewater. Appl Environ Microbiol 2002; 68 (3): 1436-1439
41. Tomb JF, White O, Kerlavage AR et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 1997; 388 (6642): 539-547
42. Wheeldon TU, Hoang TT, Phung DC et al. Long-term follow-up of Helicobacter pylori eradication therapy in Vietnam: reinfection and clinical outcome. Aliment Pharmacol Ther 2005; 21 (8): 1047-1053
43. Feydt-Schmidt A Kindermann A Konstantopoulos N et al. Reinfection rate in children after successful Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2002; 14 (10): 1119-1123
44. Svennerholm AM, Lundgren A. Progress in vaccine development against Helicobacter pylori. FEMS Immunol Med Microbiol 2007; 50 (2): 146-156
45. Wilson KT, Crabtree JE. Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007; 133 (1): 288-308
46. Kivi M, Tmdberg Y. Helicobacter pylori occurrence and transmission: a family affair? ScandJ Infect Dis 2006; 38 (6-7): 407-417
47. Kuepper-Nybelen J, Thefeld W, Rothenbacher D et al. Patterns of alcohol consumption and Helicobacter pylori infection: results of a population-based study from Germany among 6545 adults. Aliment Pharmacol Ther 2005 ; 21 (1): 57-64
48. Merzger WG, Mansouri E, Kronawitter M et al. Impact of vector-priming on the immunogenicity of a live recombinant Salmonella enterica serovar typhi Ty21 a vaccine expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2004; 22 (17-18): 2273-2277
49. Graham DY, Opekun AR, Osato MS et al. Challenge model for Helicobacter pylori infection in human volunteers. Gut 2004; 53 (9): 1235-1243
50. Losonsky GA, Kotloff KL, Walker RI. B cell responses in gastric antrum and duodenum following oral inactivated Helicobacter pylori whole cell (HWC) vaccine and LT(R192G) in H pylori seronegative individuals. Vaccine 2003; 21 (5-6): 562-565
51. Banerjee S, Medina-Fatimi A, Nichols R et al. Safety and efficacy of low dose Escherichia coli enterotoxin adjuvant for urease based oral immunisation against Helicobacter pylori in healthy volunteers. Gut 2002; 51 (5): 634-640
52. Rupnow MF, Shachter RD, Owens DK et al. Quantifying the population impact of a prophylactic Helicobacter pylori vaccine. Vaccine 2001 ; 20 (5-6): 879-885
53. Kotloff KL, Sztein MB, Wasserman SS et al. Safety and immunogenicity of oral inactivated whole-cell Helicobacter pylori vaccine with adjuvant among volunteers with or without subclinical infection. Infect Immun 2001; 69 (6): 3581-3590
54. Bumcmn D, Metzger WG, Mansouri E et al. Safety and immunogenicity of live recombinant Salmonella enterica serovar Typhi Ty21 a expressing urease A and B from Helicobacter pylori in human volunteers. Vaccine 2001 ; 20 (5-6): 845-852
55. Angelakopoulos H, Hohmann EL Pilot study of phoP/phoQ-deleted Salmonella terica serovar typhimurium expressing Helicobacter pylori urease in adult volunteers. Infect Immun 2000; 68 (4): 2135-2141
56. Rupnow MF, Owens DK, Shachter R et al. Helicobacter pylori vaccine development and use: a cost-effectiveness analysis using the Institute of Medicine Methodology. Helicobacter 1999; 4 (4): 272-280
57. Michetti P, Kreiss C, Kotloff KL et al. Oral immunization with urease and Escherichia coli heat-labile enterotoxin is safe and immunogenic in Helicobacter pylori-infected adults. Gastroenterology 1999; 116 (4): 804-812
58. DiPetrillo MD, Tibbetts T, Kleanthous H et al. Safety and immunogenicity of phoP/phoQ-deleted Salmonella typhi expressing Helicobacter pylori urease in adult volunteers. Vaccine 1999; 18 (5-6): 449-459
59. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. Bmj 1991 ; 302 (6788): 1302-1305
60. Forman D, Sitas F, Newell DG et al. Geographic association of Helicobacter pylori antibody prevalence and gastric cancer mortality in rural China. Int J Cancer 1990; 46 (4): 608-611
61. Stolte M, Eidt S. Lymphoid follicles in antral mucosa: immune response to Campylobacter pylori? J Clin Pathol 1989; 42 (12): 1269-1271
62. NIH Consensus Conference. Helicobacter pylori in peptic ulcer disease. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Jama 1994; 272 (1): 65-69
63. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol 1994; 89(8): 1137-1139
64. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and the risk for duodenal and gastric ulceration. Ann Intern Med 1994; 120 (12): 977-981
65. Huang JQ, Sridhar S, Chen Y et al. Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 1998; 114(6): 1169-1179
66. Danesh J. Helicobacter pylori infection and gastric cancer: systematic review of the epidemiological studies. Aliment Pharmacol Ther 1999; 13 (7): 851-856
67. Esilck GD, Lim LL BylesJE et al. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol 1999; 94 (9): 2373-2379
68. Xue FB, Xu YY, Wan Y et al. Association of H. pylori infection with gastric carcinoma: a Meta analysis. World J Gastroenterol 2001 ; 7 (6): 801-804
69. Huang JQ, Zheng GF, Sumanac K et al. Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology 2003; 125 (6): 1636-1644
70. Helicobacter and Cancer Collaborative Group. Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001; 49 (3): 347-353
71. Brenner H, Arndt V, Stegmaier C et al. Is Helicobacter pylori infection a necessary condition for noncardia gastric cancer? Am J Epidemiol 2004; 159 (3): 252-258
72. Parsonnet J, Hansen S, Rodriguez L et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330 (18): 1267-1271
73. Lehours P, Dupouy S, Bergey B et al. Identification of a genetic marker of Helicobacter pylori strains involved in gastric extranodal marginal zone B cell lymphoma of the MALT-type. Gut 2004; 53 (7): 931-937
74. Solnick JV, Schauer DB. Emergence of diverse Helicobacter species in the pathogenesis of gastric and enterohepatic diseases. Clin Microbiol Rev 2001; 14 (1): 59-97
75. Morgner A, Lehn N, Andersen LP et al. Helicobacter heilmannii-associ-ated primary gastric low-grade MALT lymphoma: complete remis-sion after curing the infection. Gastroenterology 2000; 118 (5): 821-828
76. Noone PA, Waclawski ER, Watt AD. Are endoscopy nurses at risk of in-fection with Helicobacter pylori from their work? Occup Med 2006; 56 (2): 122-128
77. Mastromarino P, Conti C, Donato K et al. Does hospital work constitute a risk factor for Helicobacter pylori infection? J Hosp Infect 2005; 60 (3): 261-268
78. Matsuda R, Morizane T. Helicobacter pylori infection in dental professionals: a 6-year prospective study. Helicobacter 2005; 10 (4): 307-311
79. Kim N, Lim SH, Lee KH et al. Seroconversion of Helicobacter pylori in Korean male employees. Scand J Gastroenterol 2005; 40 (9): 1021-1027
80. Braden B, Duan LP, Caspary WF et al. Endoscopy is not a risk factor for Helicobacter pylori infection - but medical practice is. Gastrointest Endosc 1997; 46 (4): 305-310
81. Cutler AF, Havstad S, Ma CK et al. Accuracy of invasive and noninvasive tests to diagnose Helicobacter pylori infection. Gastroenterology 1995; 109 (1): 136-141
82. Thijs JC, van Zwet AA, Thijs WJ et al. Diagnostic tests for Helicobacter pylori: a prospective evaluation of their accuracy, without selecting a single test as the gold standard. Am J Gastroenterol 1996; 91 (10): 2125-2129
83. Laheij RJ, de Boer WA, Jansen JB et al. Diagnostic performance of biopsy-based methods for determination of Helicobacter pylori infection without a reference standard. J Clin Epidemiol 2000; 53 (7): 742-746
84. Juttner S, Vieth M, Miehlke S et al. Reliable detection of macrolide-resistant Helicobacter pylori via fluorescence in situ hybridization in formalin-fixed tissue. Mod Pathol 2004; 17 (6): 684-689
85. Lottspeich C, Schwarzer A Panthel K et al. Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection and clari-thromycin susceptibility testing of H. pylori in stool specimens from symptomatic children. J Clin Microbiol 2007; 45 (6): 1718-1722
86. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004; 20 (10): 1001-1017
87. Leodolter A, Dominguez-Munoz JE, von Arnim U et al. Validity of a modified 13C-urea breath test for pre- and posttreatment diagnosis of Helicobacter pylori infection in the routine clinical setting. Am J Gastroenterol 1999; 94 (8): 2100-2104
88. Gisbert JP, de la Morena MF, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101 (8): 1921-1930
89. Feldman RA, Deeks JJ, Evans SJ. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis 1995; 14 (5): 428-433
90. Loy CT, Irwig LM, Katelaris PH et al. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996; 91 (6): 1138-1144
91. Bayerdorffer E, Oertel H, Lehn N et al. Topographic association between active gastritis and Campylobacter pylori colonisation. J Clin Pathol 1989; 42 (8): 834-839
92. Dixon MF, Genta RM, Yardtey JH et al. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996; 20 (10): 1161-1181
93. Stolte M, Muller H, Talley NJ et al. In patients with Helicobacter pylori gastritis and functional dyspepsia, a biopsy from the incisura angularis provides useful diagnostic information. Pathol Res Pract 2006; 202 (6): 405-413
94. Guidelines for clinical trials in Helicobacter pylori infection. Working Party of the European Helicobacter pylori Study Group. Gut 1997; 41 (Suppl2):S1-S9
95. Megraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20 (2): 280-322
96. Woo JS, El Zimaity HM, Genta RM et al. The best gastric site for obtaining a positive rapid ureas test. Helicobacter 1996; 1 (4): 256-259
97. Tepes B. Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial therapy. Scand J Gastroenterol 2007; 42 (3): 330-332
98. van IJzendoorn MC, Laheij RJ, de Boer WA et al. The importance of corpus biopsies for the determination of Helicobacter pylori infection. Neth J Med 2005; 63 (4): 141-145
99. Leodolter A, Vaira D, Bazzoli F et al. European multicentre validation trial of two new non-invasive tests for the detection of Helicobacter pylori antibodies: urine-based ELISA and rapid urine test. Aliment Pharmacol Ther 2003; 18 (9): 927-931
100. Hackelsberger A Schultze V, Peitz U et al. Performance of a rapid whole blood test for Helicobacter pylori in primary care: a German multicenter study. Helicobacter 1998; 3 (3): 179-183
101. Peitz U, Baumann M, Tillenburg B et al. [Insufficient validity of a rapid blood test for diagnosis of Helicobacter pylori infection]. Med Klin 2001; 96 (12): 703-707
102. Hoang TT, Rehnberg AS, Wheeldon TU et al. Comparison of the performance of serological kits for Helicobacter pylori infection with European and Asian study populations. Clin Microbiol Infect 2006; 12 (11): 1112-1117
103. Suerbaum S. Achtman M. Helicobacter pylori: recombination, population structure and human migrations. Int J Med Microbiol 2004; 294 (2-3): 133-139
104. Ekstrom AM, Held M, Hansson LE et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 2001; 121 (4): 784-791
105. 13C-urea breath test results. Aliment Pharmacol Ther 2006; 24(10): 1453-1460
106. 13C-urea breath test, and serology. Scand J Gastroenterol 2000; 35(2): 138-141
107. Korstanje A, van Eeden S, Offerhaus GJ et al. The 13carbon urea breath test for the diagnosis of Helicobacter pylori infection in subjects with atrophic gastritis: evaluation in a primary care setting. Aliment Pharmacol Ther 2006; 24 (4): 643-650
108. Lahner E, Voira D, Figura N et al. Role of noninvasive tests (C-urea breath test and stool antigen test) as additional tools in diagnosis of Helicobacter pylori infection in patients with atrophic body gastritis. Helicobacter 2004; 9 (5): 436-442
109. Lehours P, Ruskone-Fourmestraux A, Lavergne A et al. Which test to use to detect Helicobacter pylori infection in patients with low-grade gastric mucosa-associated lymphoid tissue lymphoma? Am J Gastroenterol 2003; 98 (2): 291-295
110. Schilling D, Jakobs R, Peitz U et al. Diagnostic accuracy of (13)C-urea breath test in the diagnosis of Helicobacter pylori infection in patients with partial gastric resection due to peptic ulcer disease: a prospective multicenter study. Digestion 2001; 63 (1): 8-13
111. Laine LA, Nathwani RA, Naritoku W. The effect of GI bleeding on Helicobacter pylori diagnostic testing: a prospective study at the time of bleeding and 1 month later. Gastrointest Endosc 2005; 62 (6): 853-859
112. Lee JM, Breslin NP, Fallon C et al. Rapid urease tests lack sensitivity in Helicobacter pylori diagnosis when peptic ulcer disease presents with bleeding. Am J Gastroenterol 2000; 95 (5): 1166-1170
113. Peitz U, LeodolterA Wex T et al. Diagnostics of Helicobacter pylori infection in patients with peptic ulcer bleeding. Z Gastroenterol 2004; 42 (2): 141-146
114. Gisbert JP, Abraira V. Accuracy of Helicobacter pylori diagnostic tests in patients with bleeding peptic ulcer: a systematic review and metaanalysis. Am J Gastroenterol 2006; 101 (4): 848-863
115. Schilling D, Demel A Adamek HE et al. A negative rapid urease test is unreliable for exclusion of Helicobacter pylori infection during acute phase of ulcer bleeding. A prospective case control study. Dig Liver Dis 2003; 35 (4): 217-221
116. Brandi G, Biavati B, Calabrese C et al. Urease-positive bacteria other than Helicobacter pylori in human gastric juice and mucosa. Am J Gastroenterol 2006; 101 (8): 1756-1761
117. Urita Y, Hike K, Torii N et al. Influence of urease activity in the intestinal tract on the results of 13C-urea breath test. J Gastroenterol Hepatol 2006; 21 (4): 744-747
118. MacOni G, Vago L, Galletta G et al. Is routine histological evaluation an accurate test for Helicobacter pylori infection? Aliment Pharmacol Ther 1999; 13 (3): 327-331
119. Stolte M, Wellens E, Bethke B et al. Helicobacter heilmannii (formerly Gastrospirillum hominis) gastritis: an infection transmitted by animals? ScandJ Gastroenterol 1994; 29 (12): 1061-1064
120. Chey WD, Woods M, Scheiman JM et al. Lansoprazole and ranitidine affect the accuracy of the 14C-urea breath test by a pH-dependent mechanism. Am J Gastroenterol 1997; 92 (3): 446-450
121. Laine L, Estrada R, Trujillo M et al. Effect of proton-pump inhibitor therapy on diagnostic testing for Helicobacter pylori. Ann Intern Med 1998; 129 (7): 547-550
122. 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99 (5): 823-829
123. Graham DY, Opekun AR, Hammoud F et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. AmJ Gastroenterol 2003; 98 (5): 1005-1009
124. Levine A, Shevah O, Shabat-Sehayek V et al. Masking of 13C urea breath test by proton pump inhibitors is dependent on type of medication: comparison between omeprazole, pantoprazole, lansoprazole and esomeprazole. Aliment Pharmacol Ther 2004; 20(1): 117-122
125. Mana F, Van Laere W, Bossuyt A et al. The early effect of proton pump inhibitor therapy on the accuracy of the 13C-urea breath test. Dig Liver Dis 2005; 37 (1): 28-32
126. Manes G, Balzano A, laquinto G et al. Accuracy of the stool antigen test in the diagnosis of Helicobacter pylori infection before treatment and in patients on omeprazole therapy. Aliment Pharmacol Ther 2001 ; 15 (1): 73-79
127. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht UI Consensus Report. Gut 2007; 56 (6): 772-781
128. Stolte M, Stadelmann O, Bethke B et al. Relationships between the degree of Helicobacter pylori colonisation and the degree and activity of gastritis, surface epithelial degeneration and mucus secretion. Z Gastroenterol 1995; 33 (2): 89-93
129. Grimley CE, Holder RL, Loft DE et al. Helicobacter pylori-associated antibodies in patients with duodenal ulcer, gastric and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol 1999; 11 (5): 503-509
130. Han SR, Schneider T, Loos M et al. One-step polymerase chain reaction-based typing of Helicobacter pylori vacA gene: association with gastric histopathology. Med Microbiol Immunol 1999; 188 (3): 131-138
131. Lamarque D, Gilbert T, Roudot-Thoraval F et al. Seroprevalence of eight Helicobacter pylori antigens among 182 patients with peptic ulcer, MALT gastric lymphoma or non-ulcer dyspepsia. Higher rate of sero-reactivity against CagA and 35-kDa antigens in patients with peptic ulcer originating from Europe and Africa. Eur J Gastroenterol Hepatol 1999; 11 (7): 721-726
132. Plummer M, van Doom LJ, Franceschi S et al. Helicobacter pylori cytotoxin-associated genotype and gastric precancerous lesions. J Natl Cancer Inst 2007; 99 (17): 1328-1334
133. Scholte GH, van Doom LJ, Cats A et al. Genotyping of Helicobacter pylori in paraffin-embedded gastric biopsy specimens: relation to histological parameters and effects on therapy. Am J Gastroenterol 2002; 97 (7): 1687-1695
134. Kodama K, Ito A Nishizono A et al. Divergence of virulence factors of Helicobacter pylori among clinical isolates does not correlate with disease specificity.J Gastroenterol 1999; 34 (Suppl 11 ): 6-9
135. Breuer T, Graham DY. Costs of diagnosis and treatment of Helicobacter pylori infection: when does choosing the treatment regimen based on susceptibility testing become cost effective? Am J Gastroenterol 1999; 94 (3): 725-729
136. Romano M, Marmo R, Cuomo A et al. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1 (4): 273-278
137. Marzio L, Coraggio D, Capodicasa S et al. Role of the preliminary susceptibility testing for initial and after failed therapy of Helicobacter pylori infection with levofioxacin, amoxicillin, and esomeprazole. Helicobacter 2006; 11 (4): 237-242
138. Malfertheiner P, Peitz U, Wolle K et al. [Helicobacter pylori infection - an update for 2004]. Dtsch Med Wochenschr 2004; 129 (34-35): 1821-1826
139. Best LM, Haldane DJ, Keelan M et al. Multilaboratory comparison of proficiencies in susceptibility testing of Helicobacter pylori and correlation between agar dilution and E test methods. Antimicrob Agents Chemother 2003 ; 47 (10): 3138-3144
140. Grignon B, Tankovic J, Megraud F et al. Validation of diffusion methods for macrolide susceptibility testing of Helicobacter pylori. Microb Drug Resist 2002; 8 (1): 61-66
141. Perna F, Gatta L Figura N et al. Susceptibility of Helicobacter pylori to metronidazolee. Am J Gastroenterol 2003; 98 (10): 2157-2161
142. Ford AC, Delaney BC, Forman D et al. Eradication therapy for peptic ulcer disease in Helicobacter pylori positive patients. Cochrane Database Syst Rev 2006; 2: CD003840
143. Laine L, Hopkins RJ, Girardi LS. Has the impact of Helicobacter pylori therapy on ulcer recurrence in the United States been overstated. A meta-analysis of rigorously designed trials. Am J Gastroenterol 1998; 93 (9): 1409-1415
144. Leodolter A, Kulig M, Brasch H et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pyloriassociated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001 ; 15(12): 1949-1958
145. Liu CC, Lee CL, Chan CC et al. Maintenance treatment is not necessary after Helicobacter pylori eradication and healing of bleeding peptic ulcer: a 5-year prospective, randomized, controlled study. Arch Intern Med 2003; 163 (17): 2020-2024
146. Malferthieiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56 (6): 772-781
147. Sharma VK, Sahai AV, Corder FA et al. Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage. Aliment Pharmacol Ther 2001 ; 15 (12): 1939-1947
148. Sonnenberg A, Olson CA Zhang J. The effect of antibiotic therapy on bleeding from duodenal ulcer. Am J Gastroenterol 1999; 94 (4): 950-954
149. Blum ALTNO. Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group. N Engl J Med 1998; 339 (26): 1875-1881
150. Froehlich F, Gonvers JJ, Wietlisbach V et al. Helicobacter pylori eradication treatment does not benefit patients with nonulcer dyspepsia. Am J Gastroenterol 2001 ; 96 (8): 2329-2336
151. Kamada T, Haruma K, Hata J et al. The long-term effect of Helicobacter pylori eradication therapy on symptoms in dyspeptic patients with fundic atrophic gastritis. Aliment Pharmacol Ther 2003; 18 (2): 245-252
152. Koskenpato J. Helicobacter pylori eradication and standardized 3month omeprazole therapy in functional dyspepsia. The American journal of gastroenterology 2001; 96 (10): 2866-2872
153. Malfertheiner P. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Alimentary pharmacology 87 therapeutics 2003; 18 (6): 615-625
154. McColl K. Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. The New England journal of medicine 1998; 339 (26): 1869-1874
155. McNamara D, Buckley M, Gilvarry J et al. Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study. Helicobacter 2002; 7 (5): 317-321
156. Talley NJ VN. Absence of benefit of eradicating Helicobacter pylori in patients with nonulcer dyspepsia. The New England journal of medicine 1999; 341 (15): 1106-1111
157. Veldhuyzen vZ, Fedorak RN, Lambert J et al. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 2003; 98 (9): 1963-1969
158. Hudson N, Brydon WG, Eastwood MA et al. Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen. Aliment Pharmacol Ther 1995 ; 9 (1): 47-50
159. Loo VG, Poirier L, Miller MA et al. A Predominantly Clonal Multi-Institutional Outbreak of Clostridium difficile-Associated Diarrhea with High Morbidity and Mortality. N Engl J Med 2005; 353 (23): 2442-2449
160. Delaney JA, Dial S, Barkun A et al. Antimicrobial drugs and community-acquired Clostridium difficile-associated disease, UK. Emerg Infect Dis 2007; 13 (5): 761-763
161. Dial S, Delaney JAC, Barkun AN et al. Use of Gastric Acid-Suppressive Agents and the Risk of Community-Acquired Clostridium difficile-Associated Disease. JAMA 2005; 294(23): 2989-2995
162. Drossman DA, Dumitrascu DL Rome III: New standard for functional gastrointestinal disorders. J Gastrointestin Liver Dis 2006; 15 (3): 237-241
163. Chiba N. Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. Alimentary pharmacology & therapeutics 2004; 19 (3): 349-358
164. Talley NJ. American Gastroenterological Association medical position statement: evaluation of dyspepsia. Gastroenterology 2005; 129 (5): 1753-1755
165. Moayyedi P, Soo S, Deeks J et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; 2: CD002096
166. Vakil N. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Alimentary pharmacology & therapeutics 2006; 24 (1): 55-63
167. Wu JC, Chan FK, ChingJY et al. Effect of Helicobacter pylori eradication on treatment of gastro-oesophageal reflux disease: a double blind, placebo controlled, randomised trial. Gut 2004; 53 (2): 174-179
168. Labenz J, Blum AL Bayerdorffer E et al. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 1997; 112 (5): 1442-1447
169. Hamada H, Haruma K, Mihara M et al. High incidence of reflux oesophagitis after eradication therapy for Helicobacter pylori: impacts of hiatal hernia and corpus gastritis. Aliment Pharmacol Ther 2000; 14 (6): 729-735
170. Vakil N, Hahn B, McSorley D. Recurrent symptoms and gastro-oesophageal reflux disease in patients with duodenal ulcer treated for Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14(1): 45-51
171. Laine L, Sugg J. Effect of Helicobacter pylori eradication on development of erosive esophagitis and gastroesophageal reflux disease symptoms: a post hoc analysis of eight double blind prospective studies. AmJ Gastroenterol 2002; 97 (12): 2992-2997
172. Vakil N, Talley NJ, Stolte M et al. Patterns of gastritis and the effect of eradicating Helicobacter pylori on gastro-oesophageal reflux disease in Western patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 2006; 24 (1): 55-63
173. Pilotto A, Perri F, Leandro G et al. Effect of Helicobacter pylori eradication on the outcome of reflux esophagitis and chronic gastritis in the elderly. A randomized, multicenter, eight-month study. Gerontology 2006; 52 (2): 99-106
174. Kuipers EJ, Nelis GF, Klinkenberg-Knol EC et al. Cure of Helicobacter pylori infection in patients with reflux oesophagitis treated with long term omeprazole reverses gastritis without exacerbation of reflux disease: results of a randomised controlled trial. Gut 2004; 53 (1): 12-20
175. Malfertheiner P, Dent J, Zeijlon L et al. Impact of Helicobacter pylori eradication on heartburn in patients with gastric or duodenal ulcer disease - results from a randomized trial programme. Aliment Pharmacol Ther 2002; 16 (8): 1431-1442
176. Moayyedi P, Bardhan C, Young L et al. Helicobacter pylori eradication does not exacerbate reflux symptoms in gastroesophageal reflux disease. Gastroenterology 2001; 121 (5): 1120-1126
177. Schenk BE, Kuipers EJ, Nelis GF et al. Effect of Helicobacter pylori eradication on chronic gastritis during omeprazole therapy. Gut 2000; 46 (5): 615-621
178. Lundell L, Miettinen P, Myrvold HE et al. Lack of effect of acid suppression therapy on gastric atrophy. Nordic Gerd Study Group. Gastroenterology 1999; 117 (2): 319-326
179. Franchini M, Cruciani M, Mengoli C et al. Effect of Helicobacter pylori eradication on platelet count in idiopathic thrombocytopenic pur-pura: a systematic review and meta-analysis. J Antimicrob Chemother 2007; 60 (2): 237-246
180. Chen LH, Luo HS. Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis. World J Gastroenterol 2007; 13 (40): 5380-5383
181. Tsutsumi Y.Kanamori H, YamatoH et al. Randomized study of Helicobacter pylori eradication therapy and proton pump inhibitor monotherapy for idiopathic thrombocytopenic purpura. Ann Hematol 2005; 84 (12): 807-811
182. Suzuki T, Matsushima M, Masui A et al. Effect of Helicobacter pylori eradication in patients with chronic idiopathic thrombocytopenic purpura-a randomized controlled trial. Am J Gastroenterol 2005; 100(6): 1265-1270
183. Emilia G, Longo G, Luppi M et al. Helicobacter pylori eradication can induce platelet recovery in idiopathic thrombocytopenic purpura. Blood 2001; 97 (3): 812-814
184. Emilia G, Luppi M, Zucchini P et al. Helicobacter pylori infection and chronic immune thrombocytopenic purpura: long-term results of bacterium eradication and association with bacterium virulence profiles. Blood 2007; 110 (12): 3833-3841
185. Yoshimura M, Hirai M, Tanaka N et al. Remission of severe anemia persisting for over 20 years after eradication of Helicobacter pylori in cases of Menetrier's disease and atrophic gastritis: Helicobacter pylori as a pathogenic factor in iron-deficiency anemia. Intern Med 2003; 42 (10): 971-977
186. Kawasaki M, Hizawa K Aoyagi K et al. Menetrier's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment. Am J Gastroenterol 1997; 92 (10): 1909-1912
187. Yamada M, Sumazaki R, Adachi H et al. Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori. Eur J Pediatr 1997; 156 (3): 182-185
188. Bayerdörffer E, Ritter MM, Hatz R et al. Healing of protein losing hypertrophic gastropathy by eradication of Helicobacter pylori - is Helicobacter pylori a pathogenic factor in Menetrier's disease? Gut 1994; 35 (5): 701-704
189. Madisch A, Miehlke S, Neuber F et al. Healing of lymphocytic gastritis after Helicobacter pylori eradication therapy - a randomized, doubleblind, placebo-controlled multicentre trial. Aliment Pharmacol Ther 2006; 23 (4): 473-479
190. Chen LH, Luo HS. Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis. World J Gastroenterol 2007; 13 (40): 5380-5383
191. Choe YH, Kim SK, Son BK et al. Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents. Helicobacter 1999; 4 (2): 135-139
192. Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR et al. Helicobacter pylori associated gastritis and primary B-cell gastric lymphoma. Lancet 1991;338:1175-1176
193. Stolte M, Eidt S. Lymphoid follicles in the antral mucosa: immune response to Campylobacter pylori. J Clin Pathol 1989; 42:1269-1271
194. Stolte M. H. pylori and gastric MALT lymphoma. Lancet 1992; 339: 745-746
195. Doglioni C, Wotherspoon AC, Moschini A et al. High incidence of primary gastric lymphoma in northeastern Italy. Lancet 1992; 339: 1175-1176
196. Zaki M, Schubert ML. Helicobacter pylori and gastric lymphoma. Gastroenterology 1995; 108: 610-612
197. Hussell T, Isaacson PG, Crabtree JE et al. The response of cells from low-grade B-cell gastric lymphomas of mucosa-associated lymphoid tissue to Helicobacter pylori. Lancet 1993; 342: 571-574
198. ParsonnetJ, Freidman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127-1131
199. Isaacson PG, Spencer J. Malignant lymphoma of mucosa-associated lymphoid tissue. Histopathology 1987; 11:44-49
200. Myhre MJ, Isaacson PG. Primary B-cell gastric lymphoma - a reassessment of its histogenesis, J Pathol 1987; 152: 1-11
201. El-Zimaity HM, Wotherspoon A de Jong D. Houston MALT lymphoma Workshop. Interobserver variation in the histopathological assessment of malt/malt lymphoma: towards a consensus. Blood Cells Mol Dis 2005; 34: 6-16
202. Harris NL ,Joffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: A proposal from the international lymphoma study group. Blood 1994; 84: 1361-1392
203. Harris NL, Jaffe ES, Diebold J et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting - Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17: 3835-3849
204. Lymphoma Classification Project. A clinical evaluation of the international lymphoma study group classification of non-Hodgkin's lymphoma. Blood 1997; 89: 3909-3918
205. Musshoff K. Klinische Stadieneinteilung der nicht-Hodgkin- Lymphome. Strahlen-therapie 1977; 153: 218-222
206. Radaszkiewicz T, Dragosics B, Bauer P. Gastrointestinal malignant lymphomas of the mucosa-associated tissue: Factors relevant to prognosis. Gastroenterology 1992; 102: 1628-1638
207. Steinbach G, Ford R, Glober G et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue: an uncontrolled trial. Ann Intern Med 1999; 131: 88-95
208. Shimodaira M, Tsukamoto Y, Niwa Y et al. A proposed staging system for primary gastric lymphoma. Cancer 1994; 73: 2709-2715
209. Ruskoné-Fourmestraux A Dragosics B, Morgner A et al. Paris staging system for primary gastrointestinal lymphomas. Gut 2003; 52: 912-913
210. Morgner A Schmelz R, Thiede C et al. Therapy of gastric mucosa associated lymphoid tissue lymphoma. World J Gastroenterol 2007; 13: 3554-3566
211. Bayerdorffer E, Neubauer A Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345:1591-1594
212. Neubauer A, Thiede C, Morgner A et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89: 1350-1355
213. Wündisch T, Thiede C, Morgner A et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-8024
214. Koch P, Probst A, Berdel WE et al. Treatment results in localized primary gastric lymphoma: data of patients registered within the German multicenter study (GIT NHL 02/96). J Clin Oncol 2005; 23: 7050-7059
215. Koch P, del Valle F, Berdel WE et al. German Multicenter Study Group. Primary gastrointestinal non-Hodgkin's lymphoma: II. Combined surgical and conservative or conservative management only in localized gastric lymphoma - results of the prospective German Multicenter Study GIT NHL 01/92. J Clin Oncol 2001 ; 19: 3874-3883
216. Fischbach W, Dragosics B, Kolve-Goebeler ME et al. Primary gastric B-cell lymphoma: results of a prospective multicenter study. The German-Austrian Gastrointestinal Lymphoma Study Group. Gastroenterology 2000; 119:1191-1202
217. Raderer M, Wahrer S, Streubel B et al. Assessment of disease dissemination in gastric compared with extragastric mucosa-associated lymphoid tissue lymphoma using extensive staging: a single-center experience. J Clin Oncol 2006; 24: 3136-3141
218. Flieger D, Keller R, May A et al. Capsule endoscopy in gastrointestinal lymphomas. Endoscopy 2005; 37: 1174-1180
219. Morgner A, Miehlke S, Fischbach W et al. Complete remission of primary high-grade B-cell gastric lymphoma after cure of Helicobacter pylori infection. J Clin Oncol 2001 ; 19: 2041-2048
220. Chen LT, Lin JT, Tai JJ et al. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97: 1345-1353
221. Chen LT, Lin JT, Shyu RY et al. Prospective study of Helicobacter pylori eradication therapy in stage 1(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2001 ; 19:4245-4251
222. Boot H, de Jong D, van Heerde P et al. Role of Helicobacter pylori eradication in high-grade MALT lymphoma. Lancet 1995; 346: 448-449
223. Morgner A BayerdörfferE, Neubauer A et al. Malignant tumours of the stomach: Gastric MALT lymphoma and Helicobacter pylori. Gastroenterol Clin North Am 2000; 29: 593-607
224. Bayerdorffer E, Neubauer A Rudolph B et al. Regression of primary gastric lymphoma of mucosa-associated lymphoid tissue type after cure of Helicobacter pylori infection. MALT Lymphoma Study Group. Lancet 1995; 345: 1591-1594
225. Roggero E, Zucca E, Pinotti G et al. Eradication of Helicobacter pylori infection in primary low-grade gastric lymphoma of mucosa-associated lymphoid tissue. Ann Intern Med 1996; 124: 275-276
226. Neubauer A, Thiede C, Morgner A et al. Cure of Helicobacter pylori infection and duration of remission of low-grade gastric mucosa-associated lymphoid tissue lymphoma. J Natl Cancer Inst 1997; 89:1350-1355
227. Steinbach G, Ford R, Glober G et al. Antibiotic treatment of gastric lymphoma of mucosa-associated lymphoid tissue. An uncontrolled trial. Ann Intern Med 1999; 131: 88-95
228. Savio A, Zamboni G, Capelli P et al. Relapse of low-grade gastric MALT lymphoma after Helicobacter pylori eradication: true relapse or persistence? Long-term post-treatment follow-up of a multicenter trial in the north-east of Italy and evaluation of the diagnostic protocol's adequacy. Recent Results Cancer Res 2000; 156: 116-124
229. Morgner A, Lehn N, Andersen LP et al. Helicobacter heilmannii-associated primary gastric low-grade MALT lymphoma: complete remission after curing the infection. Gastroenterology 2000; 118: 821-828
230. Ruskone-Fourmestraux A, Lavergne A, Aegerter PH et al. Predictive factors for regression of gastric MALT lymphoma after anti-Helicobacter pylori treatment. Gut 2001 ; 48: 297-303
231. Nakamura S, Matsumoto T, Suekane H et al. Predictive value of endoscopic ultrasonography for regression of gastric low grade and high grade MALT lymphomas after eradication of Helicobacter pylori. Gut 2001;48:454-460
232. Stolte M, Bayerdorffer E, Morgner A et al. Helicobacter and gastric MALT lymphoma. Gut 2002; (Suppl 3): 19-24
233. Diz-Lois Palomares MT, Souto RuzoJ, Yanez Lopez JA et al. Early-stage gastric MALT lymphomas: eradication of H. pylori and outcome. Rev Esp Enferm Dig 2002; 94: 669-678
234. Fischbach W, Goebeler-Kolve ME, Dragosics B et al. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004; 53: 34-37
235. Wundisch T, Thiede C, Morgner A et al. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-8024
236. Wundisch T, Mosch C, Neubauer A et al. Helicobacter pylori eradication in gastric mucosa-associated lymphoid tissue lymphoma: Results of a 196-patient series. Leuk Lymphoma 2006; 47: 2110-2114
237. Sackmann M, Morgner A, Rudolph B et al. Regression of gastric MALT lymphoma after eradication of Helicobacter pylori is predicted by endosonographic staging. MALT Lymphoma Study Group. Gastroenterology 1997; 113: 1087-1090
238. Fischbach W, Goebeler-Kolve M, Starostik P et al. Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori. Lancet 2002; 360: 547-548
239. Thiede C, Wundisch T, Alpen B et al. German MALT Lymphoma Study Group. Long-term persistence of monoclonal B cells after cure of Helicobacter pylori infection and complete histologic remission in gastric mucosa-associated lymphoid tissue B-cell lymphoma. J Clin Oncol 2001; 19: 1600-1609
240. Fischbach W, Goebeler ME, Ruskone-Fourmestraux A et al. Most patients with minimal histological residuals of gastric MALT lymphoma after successful eradication of Helicobacter pylori can be managed safely by a watch and wait strategy: experience from a large international series. Gut 2007; 56: 1685-1687
241. Ott G, Katzenberger T, GreinerA et al. The t(11;18)(q21;q21) chromosome translocation is a frequent and specific aberration in low-grade but not high-grade malignant non-Hodgkin's lymphomas of the mucosa-associated lymphoid tissue (MALT-) type. Cancer Res 1997; 57: 3944-3948
242. Auer IA, Gascoyne RD, Connors JM et al. t(11;18)(q21;q21) is the most common translocation in MALT lymphomas. Ann Oncol 1997; 8: 979-985
243. Baens M, Maes B, Steyls A et al. The product of the t(11;18), an API2-MLT fusion, marks nearly half of gastric MALT type lymphomas without large cell proliferation. Am J Pathol 2000; 156: 1433-1439
244. Liu H, Ruskoné-Fourmestraux A, Lavergne-Slove A et al. Resistance of t(11;18) positive gastric mucosa-associated lymphoid tissue lymphoma to Helicobacter pylori eradication therapy. Lancet 2001; 357: 39-40
245. Liu H, Ye H, Ruskoné-Founriesrraux A et al. T(11;18)is a marker for all stage gastric MALT lymphomas that will not respond to H. pylori eradication. Gastroenterology 2002; 122: 1286-1294
246. Alpen B, Neubauer A, Dierlamm J et al. Translocation t(11;18) absent in early gastric marginal zone B-cell lymphoma of MALT type respond2 ing to eradication of Helicobacter pylori infection. Blood 2000; 95: 4014-4015
247. Nakamura T, Nakamura S, Yonezumi M et al. Helicobacter pylori and the t(11;18)(q21;q21) translocation in gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue type. Jpn J Cancer Res 2000; 91: 301-309
248. Ye H, Dogan A, Karran L et al. BCL10 expression in normal and neoplastic lymphoid tissue. Nuclear localization in MALT lymphoma. Am J Pathol 2000; 157: 1147-1154
249. Sugiyama T, Asaka M, Nakamura T et al. AP12-MALT1 chimeric transcript is a predictive marker for the responsiveness of H. pylori eradication treatment in low-grade gastric MALT lymphoma. Gastroenterology 2001; 120: 1884-1885
250. Raderer M, Streubel B, Wohrer S et al. Successful antibiotic treatment of Helicobacter pylori negative gastric mucosa associated lymphoid tissue lymphomas. Gut 2006; 55: 616-618
251. Schechter NR, Yahalom J. Low-grade MALT lymphoma of the stomach: a review of treatment options. Int J Radiat Oncol Biol Phys 2000; 46: 1093-1103
252. Schechter NR, Portlock CS, Yahalom J. Treatment of mucosa-associated lymphoid tissue lymphoma of the stomach with radiation alone. J Clin Oncol 1998; 16:1916-1921
253. Tsang RW, Gospodarowicz MK, Pintilie M et al. Localized mucosa-associated lymphoid tissue lymphoma treated with radiation therapy has excellent clinical outcome. J Clin Oncol 2003; 21: 4157-4164
254. Tsang RW, Gospodarowicz MK. Radiation therapy for localized low-grade non-Hodgkin's lymphomas. Hematol Oncol 2005; 23: 10-17
255. Mittal B, Wasserman TH, Griffith RC. Non-Hodgkin's lymphoma of the stomach. Am J Gastroenterol 1983; 78: 780-787
256. Ettinger DS, Carter D. Gastric carcinoma 16 years after gastric lymphoma irradiation. Am J Gastroenterol 1977; 68: 485-488
257. Shani A, Schutt AJ, Weiland LH. Primary gastric malignant lymphoma followed by gastric adenocarcinoma: report of 4 cases and review of the literature. Cancer 1978; 42: 2039-2044
258. Bartlett DL, Karpehjr MS, Filippa DA et al. Long-term follow-up after curative surgery for early gastric lymphoma. Ann Surg 1996; 223: 53-62
259. Kodera Y, Yamamura Y, Nakamura S et al. The role of radical gastrectomy with systematic lymphadenectomy for the diagnosis and treatment of primary gastric lymphoma. Ann Surg 1998; 227: 45-50
260. Brands F, Monig SP, Raab M. Treatment and prognosis of gastric lymphoma. Eur J Surg 1997; 163: 803-813
261. Aviles A, Nambo MJ, Neri N et al. The role of surgery in primary gastric lymphoma: results of a controlled clinical trial. Ann Surg 2004; 240: 44-50
262. Aviles A, Nambo MJ, Neri N et al. Mucosa-associated lymphoid tissue (MALT) lymphoma of the stomach: results of a controlled clinical trial. Med Oncol 2005; 22: 57-62
263. Hammel P, Haioun C, Chaumette MT et al. Efficacy of single-agent chemotherapy in low-grade B-cell mucosa-associated lymphoid tissue lymphoma with prominent gastric expression. J Clin Oncol 1995; 13: 2524-2529
264. Nakamura S, Matsumoto T, Suekane H et al. Long-term clinical outcome of Helicobacter pylori eradication for gastric mucosa-associated lymphoid tissue lymphoma with a reference to second-line treatment. Cancer 2005; 104: 532-540
265. Levy M, Copie-Bergman C, Gameiro C et al. Prognostic value of translocation t(11;18) in tumoral response of low-grade gastric lymphoma of mucosa-associated lymphoid tissue type to oral chemotherapy. J Clin Oncol 2005; 23: 5061-5066
266. Jäger G, Neumeister P, Brezinschek R et al. Treatment of extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type with cladribine: a phase 11 study. J Clin Oncol 2002; 20: 3872-3877
267. Streubel B, Ye H, Du MQ et al. Translocation t(11;18)(q21;q21) is not predictive of response to chemotherapy with 2CdA in patients with gastric MALT lymphoma. Oncology 2004; 66: 476-480
268. Raderer M, Wohrer S, Bartsch R et al. Phase II study of oxaliplatin for treatment of patients with mucosa-associated lymphoid tissue lymphoma. J Clin Oncol 2005; 23: 8442-8446
269. Conconi A, Martinelli G, Thieblemont C et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood 2003; 102: 2741-2745
270. Raderer M, Jager G, Brugger S et al. Rituximab for treatment of advanced extranodal marginal zone B cell lymphoma of the mucosa-associated lymphoid tissue lymphoma. Oncology 2003; 65: 306-310
271. Martinelli G, Laszlo D, Ferrerl AJ et al. Clinical activity of rituximab in gastric marginal zone non-Hodgkin's lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. J Clin Oncol 2005; 23: 1979-1983
272. Chaudhary N, Ozer H, Huard D et al. Successful treatment of Helicobacter pylori-negative gastric MALT lymphoma with rituximab. Dig Dis Sci 2006; 51: 775-778
273. Salar A, Bellositlo B, Serrano S et al. Persistent residual disease in t (11;18)(q21;q21) positive gastric mucosa-associated lymphoid tissue lymphoma treated with chemotherapy or rituximab. J Clin Oncol 2005; 23: 7361-7362
274. Ferreri AJ, Freschi M, Dell'Oro S et al. Prognostic significance of the histopathologic recognition of low- and high-grade components in stage I-II B-cell gastric lymphomas. Am j Surg Pathol 2001 ; 25: 95-102
275. Femri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 2007 [Epub ahead of print]
276. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927-1932
277. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-242
278. Watanabe T, Tada M, Nagai H et al. Helicobacter pylori infection induces gastric cancer in mongolian gerbils. Gastroenterology 1998; 115: 642-648
279. Ekström AM, Hansson LE, Signorello UB et al. Decreasing incidence of both major histologic subtypes of gastric adenocarcinoma-a population-based study in Sweden. BrJ Cancer 2000; 83: 391-396
280. WHO/IARC. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177-240
281. Stoicov C, Saffari R, Cai X et al. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 2004; 341: 1-17
282. Ekström AM, Eriksson M, Hansson LE et al. Occupational exposures and risk of gastric cancer in a population-based case-control study. Cancer Res 1999; 59: 5932-5937
283. Miehlke S, Kirsch C, Agha-Amiri K et al. The Helicobacter pylori vacA si, ml genotype and cagA is associated with gastric carcinoma in Germany. Int J Cancer 2000; 87:322-327
284. Ekström AM, Serafmi M, Nyrén O et al. Dietary antioxidant intake and the risk of cardia cancer and noncardia cancer of the intestinal and diffuse types: a population-based case-control study in Sweden. Int J Cancer 2000; 87: 133-140
285. González CA, Jakszyn P, Fera G et al. Meat intake and risk of stomach and esophageal adenocarcinoma within the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 345-354
286. Sung JJ, Lin SR, Ching JY et al. Atrophy and intestinal metaplasia one year after cure of H. pylori infection: a prospective, randomized study. Gastroenterology 2000; 119: 7-14
287. Dejonge PJ, Wolters LM, Steyerberg EW et al. Environmental risk factors in the development of adenocarcinoma of the oesophagus or gastric cardia: a cross-sectional study in a Durch cohort. Aliment Pharmacol Ther 2007; 26 (1): 31-39
288. Tajima Y, Yamazaki K, Makino R et al. Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer 2007; 96(1): 631-638
289. Crew KD, Neugut AI. Epidemiology of gastric cancer. World J Gastroenterol 2006; 12 (3): 354-362
290. Meining A, Stolte M. Close correlation of intestinal metaplasia and corpus gastritis in patients infected with Helicobacter pylori. Z Gastroenterol 2002; 40: 557-560
291. Matsuhisa T, Matsukura N, Yamada N. Topography of chronic active gastritis in Helicobacter pylori-positive Asian populations: age-, gender-, and endoscopic diagnosis-matched study. J Gastroenterol 2004; 39: 324-328
292. Imagawa S, Yoshihara M, Ito M et al. Evaluation of Gastric Cancer Risk Using Topography of Histological Gastritis: A Large-scaled Cross-sectional Study. Dig Dis Sci 2007 [Epub ahead of print]; 13
293. Miehlke S, Hackelsberger A ,MeiningA et al. Severe expression of corpus gastritis is characteristic in gastric cancer patients infected with Helicobacter pylori. Br J Cancer 1998; 78: 263-266
294. Meining AG, Bayerdorffer E, Stolte M. Helicobacter pylori gastritis of the gastric cancer phenotype in relatives of gastric carcinoma patients. Eur J Gastroenterol Hepatol 1999; 11: 717-720
295. Meining A, Riedl B, Stolte M. Features of gastritis predisposing to gastric adenoma and early gastric cancer. J Clin Pathol 2002; 55: 770-773
296. Oberhuber G, Stolte M. Gastric polyps: an update of their pathology and biological significance. Virchows Arch 2000; 437: 581-590
297. Malfertheiner P, Megraud F, O'Morain C et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
298. Wong BC, Lam SK, Wong WM et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194
299. Forman D, Graham DY. Review article: impact of Helicobacter pylori on society-role for a strategy of "search and eradicate". Aliment Pharmacol Ther 2004; 19 (Suppl 1): 17-21
300. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-357
301. Janssen MJ, Laheij RJ et al. The influence of pretreatment on cure rates of Helicobacter pylori eradication. Neth J Med 2004; 62: 192-196
302. Laheij RJ, Rossum LG et al. Evaluation of treatment regimens to cure Helicobacter pylori infection - a meta-analysis. Aliment Pharmacol Ther 1999; 13 (7): 857-864
303. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004; 53: 1374-1384
304. van der Wouden EJ, Thijs JC et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-1759
305. Fucrio L, Minardi ME et al. Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication. Ann Intern Med 2007; 147: 553-562
306. Furuta T, Shirai N et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet 2005; 20: 153-167
307. Gisbert JP, Khorrami S et al. Meta-analysis: Helicobacter pylori eradication therapy vs. antisecretory non-eradication therapy for the prevention of recurrent bleeding from peptic ulcer. Aliment Pharmacol Ther 2004; 19: 617-629
308. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000; 118 (Suppl 1): S2-S8
309. Huang JQ, Zheng GF et al. Do patients with non-ulcer dyspepsia respond differently to Helicobacter pylori eradication treatments from those with peptic ulcer disease? A systematic review. World J Gastroenterol 2005; 11: 2726-2732
310. Klotz U, Schwab M et al. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8
311. Lind T, Megraud F et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-253
312. Malfenheiner P, Bayerdorffer E et al. The GU-MACH study: the effect of 1-week omeprazole triple therapy on Helicobacter pylori infection in patients with gastric ulcer. Aliment Pharmacol Ther 1999; 13: 703-712
313. Malfenheiner P, Peitz U et al. What constitutes failure for Helicobacter pylori eradication therapy? Can J Gastroenterol 2003; 17 (Suppl B): 53B-57B
314. Malfenheiner P, Megraud Fetal. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781
315. Moayyedi P, Soo S et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2006; 2: CD002096
316. Morgner A, Labenz J et al. Effective regimens for the treatment of Helicobacter pylori infection. Expert Opin Investig Drugs 2006; 15:995-1016
317. Padol S, Yuan Y et al. The effect of CYP2C19 polymorphisms on H. pylori eradication rate in dual and triple first-line PPI therapies: a metaanalysis. Am J Gastroenterol 2006; 101: 1467-1475
318. Treiber G, Malfenheiner P et al. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 2007; 8: 329-850
319. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007; 133: 985-1001
320. Hopkins RJ. Current FDA-approved treatments for Helicobacter pylori and the FDA approval process. Gastroenterology 1997; 113: S126-S130
321. Graham DY, Lu H et al. A report card to grade Helicobacter pylori ther-apy. Helicobacter 2007; 12: 275-278
322. Calvet X, Garcia N et al. A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazolee or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther 2000; 14: 603-609
323. Chiba N, Rao BV et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol 1992; 87: 1716-1727
324. Gisbert JP, Khorrami S et al. Meta-analysis: proton pump inhibitors vs. H2-receptor antagonists - their efficacy with antibiotics in Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 18: 757-766
325. Graham DY, Hammoud F et al. Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. Aliment Pharmacol Ther 2003; 17: 1229-1236
326. Huang J, Hunt RH. The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazolee. Aliment Pharmacol Ther 1999; 13: 719-729
327. Treiber G. The influence of drug dosage on Helicobacter pylori eradication: a cost-effectiveness analysis. Am J Gastroenterol 1996; 91: 246-257
328. Treiber G. Treating H. pylori shorter than one week - a real future perspective? Z Gastroenterol 2000; 38: 807-812
329. Unge P. Antimicrobial treatment of H. pylori infection - a pooled efficacy analysis of eradication therapies. Eur J Surg Suppl 1998; 582: 16-26
330. Ford AC, Delaney BC et al. Eradication therapy in Helicobacter pylori positive peptic ulcer disease: systematic review and economic analysis. Am J Gastroenterol 2004; 99: 1833-1855
331. Gene E, Calvet X et al. Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis. Aliment Pharmacol Ther 2003; 17: 1137-1143
332. Kist M. Helicobacter pylori: primary antimicrobial resistance and first-line treatment strategies. Euro Surveill 2007; 12: E1-2
333. Taylor JL, Zagari M et al. Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. Arch Intern Med 1997; 157: 87-97
334. Wolle K, Leodolter A et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002; 51: 705-709
335. Fischbach LA, van Zanten S et al. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20: 1071-1082
336. Neville PM, Everett S et al. The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen. Aliment Pharmacol Ther 1999; 13: 497-501
337. Treiber G, Wittig J et al. Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study). Arch Intern Med 2002; 162: 153-160
338. Vaira D, Zullo A et al. Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: a randomized trial. Ann Intern Med 2007; 146: 556-563
339. Zullo A, De Francesco V et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-1357
340. Treiber G, Malfenheiner P et al. Treatment and dosing of Helicobacter pylori infection: when pharmacology meets clinic. Expert Opin Pharmacother 2007; 8: 329-350
341. Janssen MJ, Laheij RJ et al. Meta-analysis: the influence of pre-treatment with a proton pump inhibitor on Helicobacter pylori eradication. Aliment Pharmacol Ther 2005; 21: 341-345
342. Klotz U, Schwab M et al. CYP2C19 polymorphism and proton pump inhibitors. Basic Clin Pharmacol Toxicol 2004; 95: 2-8
343. de Bortoli N, Leonardi G et al. Helicobacter pylori eradication: a randomized prospective study of triple therapy versus triple therapy plus lactoferrin and probiotics. Am J Gastroenterol 2007; 102:951-956
344. Gotteland M, Brunser O et al. Systematic review: are probiotics
345. Tong JL, Ran ZH et al. Meta-analysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther 2007; 25:55-68
346. Leodolter A, Kulig M et al. A meta-analysis comparing eradication, healing and relapse rates in patients with Helicobacter pylori-associated gastric or duodenal ulcer. Aliment Pharmacol Ther 2001; 15: 1949-1958
347. Treiber G, Lambert JR. The impact of Helicobacter pylori eradication on peptic ulcer healing. Am J Gastroenterol 1998; 93: 1080-1084
348. Adamek RJ, Opferkuch W et al. Cure of Helicobacter pylori infection: role of duration of treatment with omeprazole and amoxicillin. Am J Gastroenterol 1996; 91: 98-100
349. van der Wouden EJ, Thijs JC et al. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-1759
350. Gisbert JP, Pajares JM. Helicobacter pylori "rescue" therapy after failure of two eradication treatments. Helicobacter 2005; 10:363-372
351. Gisbert JP, Morena F. Systematic review and meta-analysis: levofloxacin-based rescue regimens after Helicobacter pylori treatment failure. Aliment Pharmacol Ther 2006; 23: 35-44
352. Miehlke S, Schneider-Brachen W, Kirsch C et al. One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazolee and clarithromycin. Helicobacter 2008; 13: 69-74
353. Yuan Y, Thabane L et al. Levofloxacin-based rescue regimens after Helicobacter pylori treatment failure: how strong is the evidence? Aliment Pharmacol Ther 2006; 23: 1283-1285, author reply 1285-1286
354. Koletzko S, Feydt-Schmidt A Infants differ from teenagers: use of non-invasive tests for detection of Helicobacter pylori infection in children. EurJ Gastroenterol Hepatol 2001; 13: 1047-1052
355. Jones N, Fallone C, Flook N et al. Consensus Conference: Update on the Management of Helicobacter pylori- An evidence-based evaluation of Helicobacter pylori infection and clinical sequelae in children and adolescents. Can J Gastroenterol 2005; 19: 398-408
356. Dmmm B, Koletzko S, Oderda G. Helicobacter pylori infection in children: A consensus statement. J Pediatr Gastroenterol Nutr 2000; 30: 207-213
357. Koletzko S, Richy F, Bontems P et al. Prospective multicenter study on antibiotic resistance of Helicbacter pylori strains obtained from children living in Europe. Gut 2006; 55: 1711-1716
358. Kurugoglu S, Mihmanli 1, Celkan T et al. Radiological features in paediatric primary gastric MALT lymphoma and association with Helicobacter pylori. Pediatr Radiol 2002; 32: 82-87
359. Lionetti E, Miniello VL Castellaneta SP et al. Lactobacillus reuteri therapy to reduce side-effects during anti-Helicobacter pylori treatment in children: a randomized placebo controlled trial. Aliment Pharmacol Ther 2006; 24: 1461-1468
360. Khurana R, Fischbach L, Chiba N et al. Meta-analysis: Helicobacter pylori eradication treatment efficacy in children. Aliment Pharmacol Ther 2007; 25: 523-536
361. Oderda G, Shcherbakov P, Bontems P et al. Results from the pediatric European register for treatment of Helicobacter pylori (PERTH). Helicobacter 2007; 12: 150-156
362. Feydt-Schmidt A, Kindermann A, Konstantopoulos N et al. Reinfection rate in children after successful Helicobacter pylori eradication. Eur J Gastroenterol Hepatol 2002; 14: 1119-1123
363. Rowland M, Kumar D, Daly L et al. Low rates of Helicobacter pylori reinfection in children. Gastroenterology 1999;117: 336-341
364. Rasquin A, Di Lorenzo C, Forbes D et al. Childhood functional gastrointestinal disorders: child/adolescent. Gastroenterology 2006; 130: 1527-1537
365. Kohli R, Li BUK. Differential diagnosis of recurrent abdominal pain: new considerations. Pediatric Annals 2004; 33:113-122
366. Chitkara DK, Rawat DJ, Talley NJ. The epidemiology of childhood recurrent abdominal pain in Western countries: a systematic review. AmJ Gastroenterol 2005; 100: 1868-1875
367. Hyams JS, Burke G, Davis PM et al. Abdominal pain and irritable bowel syndrome in adolescents: a community-based study. J Pediatr 1996; 129: 220-226
368. Apley J, Naish N. Recurrent abdominal pains: A field survey of 1000 school children. Arch Dis Child 1957; 33: 165-170
369. Tmdberg Y, Nyren O, Blennow M et al. Helicobacter pylori infection and abdominal symptoms among Swedish school children. J Pediatr Gastroenterol Nutr 2005; 41: 33-38
370. Falsafl T, Valizadeh N, Sepehr S et al. Application of a stool antigen test to evaluate the incidence of Helicobacter pylori infection in children and adolescents from Tehran, Iran. Clin Diagn Lab Immunol 2005; 12: 1094-1097
371. Leandro liberate SV, Hernandez Galindo M, Torroba Alvarez L et al. Helicobacter pylori infection in the child population in Spain: prevalence, related factors and influence on growth. Ann Pediatr 2005; 63: 489-494
372. Bode G, Brenner H, Adler G et al. Recurrent abdominal pain in children: evidence from a population-based study that social and familial factors play a major role but, not Helicobacter pylori infection. J Psychosom Res 2003; 54: 417-421
373. Bode G, Rothenbacher D, Brenner H et al. Helicobacter pylori and abdominal symptoms: a population-based study among preschool chidren in southern Germany. Pediatrics 1998; 101: 634-637
374. Macarthur C, Saunders N, Feldman W. Helicobacter pylori, gastroduodenal disease, and recurrent abdominal pain in children. JAMA 1995; 273: 729-734
375. Macarthur C, Saunders N, Feldman W et al. Helicobacter pylori and childhood recurrent abdominal pain: community based case-control study. BMJ 1999; 319: 822-823
376. Kalach N, Mention K, Guimber D et al. Helicobacter pylori infection is not associated with specific symptoms in nonulcer-dyspeptic children. Pediatrics 2005; 115: 17-21
377. Das BK, Kakkar S, Dixit VK et al. Helicobacter pylori infection and recurrent abdominal pain in children.J Trop Pediatr 2003; 49: 250-252
378. Frank F, Strieker T, Stallmach T et al. Helicobacter pylori infection in recurrent abdominal pain. J Pediatr Gastroenterol Nutr 2000; 31: 424-427
379. Wewer V, Andersen IP, Paenegaard A et al. Treatment of Helicobacter pylori in children with recurrent abdominal pain. Helicobacter 2001 ; 6: 244-248
380. Alfven G. One hundred cases of recurrent abdominal pain in children: diagnostic procedures and criteria for a psychosomatic diagnosis. Acta Paediatr 2003; 92: 43-49
381. Ukarapol N, Lertprasertsuk N, Wongsawasdi L Recurrent abdominal pain in children: the utility of upper endoscopy and histopathology. Singapore Med J 2004; 45: 121-124
382. Ashorn M, Rago T, Kokkonen J et al. Symptomatic response to Helicobacter pylori eradication in children with recurrent abdominal pain: double blind randomized placebo-controlled trial.J Clin Gastroenterol 2004; 38: 646-650
383. Rafeey M. Jafari-Rouhi AH, Gassemi BA et al. Relationship between endoscopic nodular gastritis and Helicobacter pylori infection in children. Indian J Gastroenterol 2004; 23: 138-139
384. Bahu MG, da Silveira TR, Maguilnick I et al. Endoscopic nodular gastritis: an endoscopic indicator of high-grade bacterial colonization and severe gastritis in children with Helicobacter pylori. J Pediatr Gastroenterol Nutr 2003; 36: 217-222
385. Luzza F, Pensabene L, lmeneo M et al. Antral nodularity and positive CagA serology are distinct and relevant markers of severe gastric inflammation in children with Helicobacter pylori infection. Helicobac-ter 2002; 7: 46-52
386. Ganga ZP, Michaud L Vincent P et al. Natural outcome of Helicobacter pylori infection in asymptomatic children: a two-year follow-up study. Pediatrics 1999; 104: 216-221
387. Barabino A, Dufour C, Marino CE et al. Unexplained refractory irondeficiency anemia associated with Helicobacter pylori gastric infection in children: Further clinical evidence. J Pediatr Gastroenterol Nutr 1999; 28/1: 116-119
388. Ashorn M, Ruuska T, Makipemaa A. Helicobacter pylori and iron deficiency anaemia in children. Scand J Gastroenterol 2001 ; 36: 701-705
389. Choe YH, Lee JE, Kim SK. Effect of Helicobacter pylori eradication on sideropenic refractory anaemia in adolescent girls with Helicobacter pylori infection. Acta Paediatr 2000; 89: 154-157
390. Choe YH, Kim SK, Son BK et al. Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in préadolescent children and adolescents. Helicobacter 1999; 4: 135-139
391. Emin-Kurekci A, Avni-Atay A, Umit-Sarici S et al. Is there a relationship between childhood Helicobacter pylori infection and iron deficiency anemia? J Trop Pediatr 2005; 51: 166-169
392. Gessner BD, Baggett HC, Muth PT et al. A controlled, household-randomized, open-label trial of the effect that treatment of Helicobacter pylori infection has on iron deficiency in children in rural Alaska. J Infect Dis 2006; 193: 537-546
393. Kerr JG, AI-Khattaf A, Barson AJ et al. An association between sudden infant death syndrome (SIDS) and Helicobacter pylori infection. Arch Dis Child 2000; 83: 429-434
394. Karlidag T, Bulut Y, Keles E et al. Detection of Helicobacter pylori in children with otitis media with effusion: a preliminary report. Laryngoscope 2005; 115: 1262-1265
395. Koletzko S, Konstantopoulos N, Lehn N et al. Control your controls and conclusions. Arch Dis Child 2001; 84: 525
396. Bitar M, Mahfouz R, Soweid A et al. Does Helicobacter pylori colonize the nasopharynx of children and contribute to their middle ear disease? Acta Otolaryngol 2006; 126: 154-159
397. Vaira D, Menegatti M, Salardi S et al. Helicobacter pylori and diminished growth in children: is it simply a marker of deprivation? Ital J Gastroenterol Hepatol 1998; 30: 129-133
398. Richter T, Richter T, List S et al. Five- to 7-year-old children with Helicobacter pylori infection are smaller than Helicobacter-negative children: a cross-sectional population-based study of 3,315 children.J Pediatr Gastroenterol Nutr 2001 ; 33: 472-475
399. Oderda G, Palli D, Saieva C et al. Short stature and Helicobacter pylori infection in Italian children: prospective multicentre hospital based case-control study. The Italian Study Group on Short Stature and H pylori. BMJ1998; 317: 514-515
400. Pitlcaranta A, Kolho KL, Rautelin H. Helicobacter pylori in children who are prone to upper respiratory tract infections. Arch Otolaryngol Head Neck Surg 2005; 131: 256-258
401. Kindermann A, Demmelmair H, Koletzko B et al. Influence of age on 13C-urea breath test results in children.J Pediatr Gastroenterol Nutr 2000; 30: 85-91
402. 13C-urea breath test. J Pediatr Gastroenterol Nutr 1998; 27: 275-280
403. Megraud F. Comparison of non-invasive tests to detect Helicobacter pylori infection in children and adolescents: results of a multicenter European study. J Pediatr 2005; 146: 198-203
404. 13C-urea breath test for childhood Helicobacter pylori infection: a multicenter Japanese study. AmJ Gastroenterol 2002; 97: 1668-1673
405. Herold R, Becker M. 13C-urea breath test threshold calculation and evaluation for the detection of Helicobacter pylori infection in children. BMC Gastroenterol 2002; 2:12
406. Koletzko S. Noninvasive diagnostic tests for Helicobacter pylori infection in children. Can J Gastroenterol 2005; 19: 433-439
407. Imrie C, Rowland M, Bourke B et al. Limitations to carbon 13-labeled urea breath testing for Helicobacter pylori in infants. J Pediatr 2001; 139: 734-737
408. 2 production rates in children.J Pediatr Gastroenterol Nutr 1999; 29: 297-301
409. Graham DY, Opekun AR, Jogi M et al. False negative urea breath tests with H2-receptor antagonists: interactions between Helicobacter pylori density and pH. Helicobacter 2004; 9: 17-27
410. Graham DY, Opekun AR, Hammoud F et al. Studies regarding the mechanism of false negative urea breath tests with proton pump inhibitors. Am J Gastroenterol 2003; 98: 1005-1009
411. Megraud F. Non-invasive tests to detect Helicobacter pylori infection in children and adolescents: results of a multicentric European study. J Pediatr 2005; 146: 198-203
412. Koletzko S, Konstantopoulos N, Bosman D et al. Evaluation of a novel monoclonal enzyme immunoassay for detection of Helicobacter pylori antigen in stool from children. Gut 2003; 52: 804-806
413. Schwarzer A, Lottspeich C, Russmann H et al. Evaluation of a novel rapid one-step monoclonal chromatographic immunoassay for detection of Helicobacter pylori in stool from children. Eur J Clin Microbiol Infect Dis 2007; 26: 475-480
414. Hino B, Eliakim R, Levine A et al. Comparison of invasive and non-invasive tests diagnosis and monitoring of Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2004; 39: 519-523
415. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921-1930
416. Konstantopoulos N, Russmann H, Tasch C et al. Evaluation of the Helicobacter pylori stool antigen test (HpSA) for detection of Helicobacter pylori infection in children. Am J Gastroenterol 2001 ; 96: 677-683
417. Makristathis A, Barousch W, Pasching E et al. Two enzyme immunoassays and PCR for detection of Helicobacter pylori in stool specimens from Pediatric Patients before and after eradication therapy. J Clin Microbiol 2000; 38: 3710-3714
418. Antos D, Crone J, Konstantopoulos N et al. Evaluation of a novel rapid one-step immunochromatographic assay for detection of monoclonal Helicobacter pylori antigen in stool samples from children.J Clin Microbiol 2005; 43: 2598-2601
419. Lottspeich C, Schwarzer A Panthel K et al. Evaluation of the novel Helicobacter pylori ClariRes real-time PCR assay for detection and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic children. J Clin Microbiol 2007; 45: 1718-1722
420. Oliveira AMR, Rocha GA Queiroz DM et al. Evaluation of enzymelinked immunosorbent assay for the diagnosis of Helicobacter pylori infection in children from different age groups with and without duodenal ulcer [see comments]. J Pediatr Gastroenterol Nutr 1999; 28: 157-161
421. Kindermann A, Konstantopoulos N, Lehn N et al. Evaluation of two commercial enzyme immunoassays, testing immunoglobulin G (IgG) and IgA responses, for diagnosis of Helicobacter pylori infection in children.J Clin Microbiol 2001; 39: 3591-3596
422. Rocha GA, Oliveira AM, Queiroz DM et al. Immunoblot analysis of humoral immune response to Helicobacter pylori in children with and without duodenal ulcer. J Clin Microbiol 2000; 38: 1777-1781
423. Ni YH, Lin JT, HuangSFet al. Accurate diagnosis of Helicobacter pylori infection by stool antigen test and 6 other currently available tests in children [see comments]. J Pediatr 2000; 136: 823-827
424. Raymond J, Sauvestre C, Kalach N et al. Immunoblotting and serology for diagnosis of Helicobacter pylori infection in children. Pediatr Infect Dis J 2000; 19: 118-121
425. Raymond J, Sauvestre C, Kalach N et al. Evaluation of a new serologic test for diagnosis of Helicobacter pylori infection in children. Eur J Clin Microbiol Infect Dis 1999; 18: 192-198
426. Kalach N, Benhamou PH, Campeotto F et al. Clarithromycin resistance and eradication of Helicobacter pylori in children. Antimicrob Agents Chemother 2001 ; 45: 2134-2135
427. Wolle K, Leodolter A, Malfenheiner P et al. Antibiotic susceptibility of Helicobacter pylori in Germany: stable primary resistance from 1995 to 2000. J Med Microbiol 2002 ; 51: 705-709
428. Pohle T, Stoll R, Kirchner T et al. Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole - an open pilot study. Aliment Pharmacol Ther 1998; 12: 1273-1278
429. Megraud F, Lehn N, Lind T et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-2752
430. Arenz T, Antos D, Russmann H et al. Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children. J Pediatr Gastroenterol Nutr 2006; 43: 180-184
431. Feydt-Schmidt A, Russmann H, Lehn N et al. Fluorescence in situ hybridization vs. epsilometer test for detection of clarithromycin-susceptible and clarithromycin-resistant Helicobacter pylori strains in gastric biopsies from children. Aliment Pharmacol Ther 2002; 16: 2073-2079
432. Rüssmann H, Feydt-Schmidt A, Adler K et al. Detection of Helicobacter pylori in paraffin-embedded and in shock-frozen gastric biopsy samples by fluorescent in situ hybridization. J Clin Microbiol 2003; 41: 813-815
433. Drumm B, RhoadsJM, Stringer DA et al. Peptic ulcer disease in children: etiology, clinical findings, and clinical course. Pediatrics 1988; 82: 410-414
434. Kivi M, Tmdberg Y, Sorberg M et al. Concordance of Helicobacter pylori strains within families. J Clin Microbiol 2003; 41: 5604-5608
435. Crone J, Granditsch G, Huber WD et al. Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000. J Pediatr Gastroenterol Nutr 2003; 36: 368-371
436. Francavilla R, Lionetti E, Castellaneta SP et al. Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial. Gastroenterology 2005; 129: 1414-1419
437. Zullo A, De Francesco V, Hassan C et al. The sequential therapy regimen for Helicobacter pylori eradication: a pooled-data analysis. Gut 2007; 56: 1353-1357
438. Miehlke S, Kirsch C, Schneider-Brachen W et al. A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin. Helicobacter 2003; 8: 310-319
439. Gatta L, Vakil N, Ricci C et al. Effect of proton pump inhibitors and antacid therapy on 13C urea breath tests and stool test for Helicobacter pylori infection. Am J Gastroenterol 2004; 99: 823-829
440. Miehlke S, Bayerdorffer E, Lehn N et al. Recurrence of duodenal ulcers during five years of follow-up after cure of Helicobacter pylori infection. Eur J Gastroenterol Hepatol 1995; 7: 975-978
441. Kalach N, Bergeret M, Benhamou PH et al. High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children. J Clin Microbiol 2001 ; 39: 394-397
442. Hansen JM, Hallos J, Lauritsen JM et al. Non-steroidal anti-inflammatory drugs and ulcer complications: a risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996; 31: 126-130
443. Hernandez-Diaz S, Rodriguez LA. Association between nonsteroidal anti-inflammatory drugs and upper gastrointestinal tract bleeding/perforation: an overview of epidemiologic studies published in the 1990s. Arch Intern Med 2000; 160: 2093-2099
444. Hawkey CJ, Weinstein WM, Smalley W et al. Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study. Gastroenterology 2007; 133: 57-64
445. Henry D, Lim U, Garcia Rodriguez LA et al. Variability in risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaborative meta-analysis. BMJ 1996; 312: 1563-1566
446. Weil J, Longman MJ, Wainwright P et al. Peptic ulcer bleeding: accessory risk factors and interactions with non-steroidal anti-inflammatory drugs. Gut 2000; 46: 27-31
447. Scheiman JM, Yeomans ND, Talley NJ et al. Prevention of ulcers by esomeprazole in at-risk patients using non-selective NSAlDs and COX-2 inhibitors. Am J Gastroenterol 2006; 101: 701-710
448. Miyake K, Ueki N, Suzuki K et al. Preventive therapy for non-steroidal anti-inflammatory drug-induced ulcers in Japanese patients with rheumatoid arthritis: the current situation and a prospective controlled-study of the preventive effects of lansoprazole or famotidine. Aliment Pharmacol Ther 2005; 21 (Suppl 2): 67-72
449. Stupnicki T, Dietrich K, Gonzalez-Carro P et al. Efficacy and tolerability of pantoprazole compared with misoprostol for the prevention of NSAID-related gastrointestinal lesions and symptoms in rheumatic patients. Digestion 2003; 68: 198-208
450. Labenz J, Blum AL, Bolten WW et al. Primary prevention of diclofenac associated ulcers and dyspepsia by omeprazole or triple therapy in Helicobacter pylori positive patients: a randomised, double blind, placebo controlled, clinical trial. Gut 2002; 51: 329-335
451. Graham DY, Agrawal NM, Campbell DR et al. Ulcer prevention in longterm users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 2002; 162: 169-175
452. Silverstein FE, Faich G, Goldstein JL et al. Gastrointestinal toxicity with celecoxib vs. nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-1255
453. Bombardier C, Laine L, Reicin A et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-1528,1522p following 1528
454. Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 2002; 347: 2104-2110
455. Chan FK, Hung LC, Suen BY et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. Gastroenterology 2004; 127: 1038-1043
456. Hooper L, Brown TJ, Elliott R et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ 2004; 329: 948
457. Kearney PM, Baigent C, Godwin J et al. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006; 332: 1302-1308
458. Rostom A, Muir K, Dube C et al. Gastrointestinal safety of cyclooxygenase-2 inhibitors: a Cochrane Collaboration systematic review. Clin Gastroenterol Hepatol 2007; 5: 818-828,828 e811-815, quiz 768
459. Chan FK, WongVW, Suen BY et al. Combination of a cyclo-oxygenase-2 inhibitor and a proton-pump inhibitor for prevention of recurrent ulcer bleeding in patients at very high risk: a double-blind, randomised trial. Lancet 2007; 369: 1621-1626
460. Goldstein JL, Cryer B, Amer F et al. Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: a randomized, double-blind, endoscopic trial. Clin Gastroenterol Hepatol 2007; 5: 1167-1174
461. Stack WA, Athenon JC, Hawkey GM et al. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002; 16: 497-506
462. Chan FK, To KF, WuJC et al. Eradication of Helicobacter pylori and risk of peptic ulcers in patients starting long-term treatment with non-steroidal anti-inflammatory drugs: a randomised trial. Lancet 2002; 359: 9-13
463. Lai KC, Lau CS, Ip WY et al. Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2003; 17: 799-805
464. Vergara M, Catalan M, Gisbert JP et al. Meta-analysis: role of Helicobacter pylori eradication in the prevention of peptic ulcer in NSAlD users. Aliment Pharmacol Ther 2005; 21: 1411-1418
465. Lai KC, Lam SK, Chu KM et al. Lansoprazole reduces ulcer relapse after eradication of Helicobacter pylori in nonsteroidal anti-inflammatory drug users - a randomized trial. Aliment Pharmacol Ther 2003; 18: 829-836
466. Hawkey CJ, Tulassay Z, Szczepanski L et al. Randomised controlled trial of Helicobacter pylori eradication in patients on non-steroidal antiinflammatory drugs: HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-1021
467. Chan FK, Chung SC, Suen BY et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973
468. WeilJ, Colin-Jones D, Longman M et al. Prophylactic aspirin and risk of peptic ulcer bleeding. BMJ 1995; 310: 827-830
469. Kelly JP, Kaufman DW, Jurgelon JM et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996; 348: 1413-1416
470. SlatteryJ, Warlow CP, Shorrock CJ et al. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirinanalysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509-511
471. Yeomans ND, Lanas Al, Talley NJ et al. Prevalence and incidence of gastroduodenal ulcers during treatment with vascular protective doses of aspirin. Aliment Pharmacol Ther 2005; 22: 795-801
472. Lanas A, FuentesJ, Benito R et al. Helicobacter pylori increases the risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-786
473. Lai KC, Lam SK, Chu KM et al. Lansoprazole for the prevention of recurrences of ulcer complications from long-term low-dose aspirin use. N Engl J Med 2002; 346: 2033-2038
474. Chan FK, Ching JY, Hung LC et al. Clopidogrel versus aspirin and esomeprazole to prevent recurrent ulcer bleeding. N Engl J Med 2005; 352: 238-244
475. Lai KQ Chu KM, Hui WM et al. Esomeprazole with aspirin versus Clopidogrel for prevention of recurrent gastrointestinal ulcer complications. Clin Gastroenterol Hepatol 2006; 4: 860-865
476. Hallas J, Dall M, Andries A et al. Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study. BMJ 2006; 333: 726
477. Summers RW, Switz DM, Sessions Jr JT et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77: 847-869
478. Malchow H, Ewe K, Brandes JW et al. European Cooperative Crohn's Disease Study (ECCDS): results of drug treatment. Gastroenterology 1984;86:249-266
479. Guslandi M, Tittobello A. Symptomatic response to omeprazole in inflammatory bowel disease.J Clin Gastroenterol 1996; 22: 159-160
480. Dickinson JB. Is omeprazole helpful in inflammatory bowel disease? J Clin Gastroenterol 1994; 18: 317-319
481. Cheung AN, Ng IO. Cytomegalovirus infection of the gastrointestinal tract in non-AIDS patients. Am J Gastroenterol 1993; 88: 1882-1886
482. Dorigo-Zetsma JW, van der Meer JT, Tersmette M et al. Value of laboratory investigations in clinical suspicion of cytomegalovirus-induced upper gastrointestinal tract ulcerations in HIV-infected patients. J Med Virol 1996; 49: 29-33
483. Peter A, Telkes G, Varga M et al. Endoscopie diagnosis of cytomegalovirus infection of upper gastrointestinal tract in solid organ transplant recipients: Hungarian single-center experience. Clin Transplant 2004; 18: 580-584
484. Pruittjr BA, Foley FD, Moncrief JA. Curling's ulcer: a clinical-pathology study of 323 cases. Ann Surg 1970; 172: 523-539
485. Cook DJ, Fuller HD, Guyatt GH et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994; 330: 377-381
486. Cook DJ, Reeve BK, Guyatt GH et al. Stress ulcer prophylaxis in critically ill patients. Resolving discordant meta-analyses. Jama 1996; 275: 308-314
487. Tryba M, Cook D. Current guidelines on stress ulcer prophylaxis. Drugs 1997; 54: 581-596
488. Rosen HR, Vlahakes GJ, Rattner DW. Fulminant peptic ulcer disease in cardiac surgical patients: pathogenesis, prevention, and management. Crit Care Med 1992; 20: 354-359
489. Janicki T, Stewart S. Stress-ulcer prophylaxis for general medical patients: a review of the evidence. J Hosp Med 2007; 2: 86-92